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Background Pulmonary fibrosis / intersitial lung disease 
(ILD) in systemic sclerosis (SSc) is a complicated 
restrictive pulmonary disease and the leading cause of 
disease-related mortality. Progressive skin fibrosis in 
diffuse-type SSc (dSSc) is associated with decreased 
forced vital capacity (FVC). Modified Rodnan Skin Score 
(mRSS) examination is used as a parameter to assess 
skin fibrosis, while high-resolution computed tomography 
(HRCT) and pulmonary function tests (PFTs) are used to 
assess pulmonary fibrosis. The HRCT test remains as 
the gold standard in diagnosing ILD. However, it costs a 
lot and is not available in all healthcare facilities. Krebs 
Von den Lungen-6 (KL-6) is a biomarker to evaluate 
pulmonary fibrosis. The aim of this study was to analyze 
the correlation of serum KL-6 levels with FVC and mRSS 
value of patients with restrictive lung disease in dSSc. 
Method This was a cross-sectional study that  
used primary data from dSSc patients who visited 
rheumatology outpatient clinic in Hasan Sadikin Hospital 
Bandung, Indonesia, during the period of June-July 2019. 
History taking, physical examination, mRSS, spirometry, 
and serum KL-6 levels were performed. Data were 
analyzed using the Rank Spearman correlation test. 
Result There were 27 subjects with the mean age of 42 
± 12 years. Based on FVC (%) restrictive lung disease 
criteria, the majority of subjects (74.1%) had severe 
restrictive lung disease and the rest of all subjects 
 
(25.9%) were non severe restrictive lung disease. 
Serum KL-6 levels ranged from 0.545 to 8.138 ng/ml. 
The results showed that there was no correlation 
between serum KL-6 levels and FVC values (r = -
0.118, p = 0.279) and mRSS (r = 0.101, p = 0.312 ). 
 
Conclusion There is no correlation between serum KL-6 
levels with FVC and mRSS value of patient with restritive 
lung disease in diffuse type systemic sclerosis. 
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Systemic sclerosis (SSc) is a chronic and progressive 
autoimmune disease hallmarked by the distinctive 
triad of microvascular damage, dysregulation of 
innate and adaptive immunity, and most importantly, 
generalized fibrosis in multiple 
 
 
organs.1 Interstitial lung disease (ILD) is the most 
common pulmonary manifestation of SSc, affecting 
about 40% of patients, and by far the leading cause of 
morbidity and mortality.2,3 Patients with SSc who 
develop ILD have increased mortality by 2.9-fold 
when compared with SSc patients without ILD.4 
Furthermore, based on autopsy series performed in 
SSc patients, pulmonary fibrosis was found in 90 
percent of cases.6 For those particular reasons, 
evaluation of ILD in SSc patients is necessary.  
High Resolution Computed Tomography 
(HRCT) scanning remains as the standard and the 
most sensitive method in diagnosing ILD.7,8 
However, HRCT is not available in all healthcare 
facilities and also not affordable for most patients.9 
Hence, pulmonary function test (PFT) is commonly 
used to screen and evaluate long term pulmonary 
function. Decreased forced vital capacity (FVC) 
determines the severity level of restrictive lung 
disorder.  
More extensive skin thickening corresponds with 
more severe visceral organ manifestation.10 Modified 
Rodnan skin score (mRSS) is considered as the most 
appropriate tools in estimating skin fibrosis in SSc.10 
The progressivity of skin fibrosis in diffuse type SSc 
(dSSc), which is more severe compared with limited 
type SSc (lSSc), is associated with decline in lung 
function and worse survival.11 It is a challenge for 
clinicians to identify ILD in earlier stage of SSc. 
Therefore, biomarker that could easily detect and 
significantly portraying lung fibrosis activity is 
necessary.  
Recent studies found that Krebs von den 
Lungen-6 (KL-6) is expressed by alveolar 
pneumocyte and increased in serum when there is 
fibrogenesis activity in the lungs.12,13 However, the 
correlation between KL-6 with FVC and mRSS is 
still controversial. This study is the pilot study in 
Indonesia to analyze the correlation between serum 
KL-6 levels with FVC and mRSS value of patients 
with restrictive lung disease in dSSc. 
 
Method 
This was a cross-sectional study conducted in 
rheumatology outpatient clinic of Hasan Sadikin 
Hospital Bandung, Indonesia from June until 
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July 2019. The subjects were dSSc patients with restrictive lung 
disorder confirmed by spirometry test evaluated by the 
pulmonologist in Hasan Sadikin Hospital Bandung. Decreased FVC 
of <80% and increased FEV1/FVC ratio > 0.7 were defined as 
restrictive lung disorder. The patients whom spirometry results met 
these criteria were included as the subjects in this study. The 
exclusion criteria were as followed: 1) other autoimmune diseases 
that can cause restrictive lung disorder (i.e. rheumatoid arthritis, 
systemic lupus erythematosus, ankylosing spondylitis, and Sjogren 
syndrome), 2) restrictive lung disorder caused by the other diseases 
than SSc, 3) malignancy, 4) pneumonia, TB pulmonary, asthma 
bronchiale, and bronchiectasis, 5) hepatitis, cholecystitis, and 
pancreatitis,  
6) pregnancy and lactation. These exclusion criteria were 
based on previous studies that reported an elevated level of 
KL-6 on those diseases and pregnancy that could lead to bias 
in this study.13  
History taking, physical examination, and other supporting 
examination written in subjects’ medical record were 
evaluated to exclude the subject. This study collected primary 
data consisting of serum KL-6 from subjects, their skin 
fibrosis condition assessed by mRSS, and FVC value 
measured by spirometry test. KL-6 / human mucin-1 (Human 
MUC-1, ng/ mL) serum were measured from 5 milliliters of 
venous blood sample with ELISA sandwich method.  
Baseline characteristics, including age, gender, duration of 
disease, clinical manifestation, and treatment history received 
by subjects, were also collected during the visit. Statistical 
analysis used in this study were Spearman correlation test. 
This study also has been approved by Hasan Sadikin General 
Hospital Ethics and Research Committee. 
 
Result 
There were 27 subjects included in this study and all of them 
were female with the mean age of 42 years old. Characteristics 
of the subjects were shown in Table 1. Median value of KL-6 
serum was 2.999 ng/mL with the range of 0.545 – 8.138 ng/ 
mL. Median score of mRSS of the subjects was 23 (range: 5-
45) and mean of FVC percentage was 52%. There were 21 
subjects who had received methotrexate as disease-modifying 
antirheumatic drugs (DMARDs) before, 3 subjects who had 
DMARDs other than methotrexate (azathioprine and 
cyclophosphamide), and 3 subjects who were DMARDs 
naive.  
This study showed a very weak negative correlation 
between KL-6 serum and FVC value. However it was not 
significant (r = -0,118, p= 0,279) as shown in Table 2 and 
Figure 1. On the other hand, there was a weak positive 
correlation between KL-6 serum and mRSS score which was 
not significant either (r = 0,101, p=0,312, Table 3) 
 
 Original Article 
Table 1. Characteristics of Subjects  
  
Variable n=27 
Age (years), mean ± SD 42±12 
Gender, n (%)   
Female 27 (100) 
Male 0 (0) 
Duration of disease (years), median (range) 3(1–23) 
Treatment history, n (%)   
Methotrexate 21 (77.8) 
Steroid (methylprednisolone) 23 (85.2) 
Cyclophosphamide 2 (7.4) 
Mycophonelate mofetil  - 
Azathioprine 1 (3.7) 
Calcium Channel Blocker (CCB) 27 (100) 
PPI/H2 Antagonist 17 (63) 
Aspilet 24 (88.9) 
Never receive any treatment before 3 (11.1) 
Laboratory results, mean ± SD   
Hemoglobin (gr/dl) 12.6 ± 1.5 
Leukocyte (/mm3) 9,500 ± 3,500 
Thrombocyte (/mm3) 327,000 ± 86,000 
Creatinin (mg/dl) 0.66 ± 0.19 
SGPT (U/L) 22±6 
Krebs von den Lungen-6 (ng/ml) , median 2.3 (0.5 – 8.1) 
(range)   
Clinical manifestation based on ACR/ EULAR,   
n (%)   
Raynaud’s phenomenon 27 (100) 
Fibrosis of both arms 27 (100) 
Sclerodactyly 25 (92.6) 
Puffy fingers  - 
Telangiectasis 20 (74.1) 
Scar of fingers 15 (55.6) 
Calcinosis  - 
mRSS, median (range) 23 (5 – 45) 
FVC (%), mean ± SD 52±11 
Restrictive lung disorder, n (%)   
Mild to moderate (FVC 60-79%) 7 (25.9) 
Severe (FVC ≤59%) 20 (74.1)   
Notes: standard deviation (SD), antinuclear antibodies (ANA), 
American College of Rheumatology (ACR), European League 
Against Rheumatism (EULAR), systemic sclerosis (SSc), 
modified Rodnan skin score (mRSS), forced vital capacity 
(FVC), serum glutamic pyruvate transaminase (SGPT) 
 
Table 2. Correlation between KL-6 serum and FVC value  
Variable 
FVC value  
Correlation coefficient (r) p-value  
   
KL-6 serum level -0,118 0,279* 
 
Notes: Krebs von den Lungen-6 (KL-6), forced vital 
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Figure 1. Scattered diagram of KL-6 level and FVC value Table 3. 





Correlation coefficient (r) p-value  
   
KL-6 serum level 0.101 0,312* 
    
Notes: modified Rodnan skin score (mRSS), forced vital 
capacity (FVC)  
















Figure 2. Scattered diagram of KL-6 level and mRSS 
 
Notes: Krebs von den Lungen-6 (KL-6), forced vital 




In this study, the mean age of SSc patients was 42 years old. This 
was echoed the findings in the other studies which stated that the 
highest SSc onset was on the third until fourth decade of life.14 A 
study in Indonesia conducted by Salim et al shown that the 
average age of SSc patients was 41 ± 11 years.9 Similar findings 
were also reported in a cohort study by Sujau et al from Malaysia 
which involved 90.3% female subjects with the mean age of 42.6 
years old.15 Another study conducted in Singapore by Low et al 
reported mean age of 46  
± 14.9 years in their subjects.16  
Range of mRSS value in this study was 5-45 with the mean 
score of 23. It was in accordance with a cohort study from 
Egypt which showed mRSS value ranged from 4 until 
 
 
45.17 Mean FVC value of the subjects was 52%. It was quite 
consistent with the findings from Salim et al study which 
stated FVC value of 58.2 ± 10.8 %.9 Classification of 
restrictive lung disorder based on FVC value in this study were 
mostly severe restrictive lung disorder (74.1%), whilst the rest 
of the subjects (25.9%) had mild to moderate restrictive lung 
disorder. This was in accordance with study by Steen et al 
which shown moderate to severe restrictive lung disorder in 
40% of subjects.18 
 
KL-6 serum with FVC value 
This study was the first study in Indonesia to analyze the 
correlation between KL-6 serum with FVC value and mRSS. 
In this study, there was no correlation between KL-6 serum 
and FVC value. It was different with another study from 
Benyamine et al and Bonela et al which showed a significant 
negative correlation between KL-6 serum and FVC value.19,20 
Benyamin et al reported in their study that KL-6 serum 
significantly correlated with FVC value (r = − 0.418; p = 
0.001) on SSc patients in France.20 Study in Italy by Bonela et 
al also showed a significant negative correlation between KL-
6 serum and FVC value (r=-0.47, p<0.05).19 Both Benyamin et 
al and Bonela et al used HRCT and PFT to assess pulmonary 
fibrosis on SSc patients.  
The difference on KL-6 serum with FVC value between this 
study and previous studies might happen due to several things. 
First, the subjects of this study have different degree of skin 
thickening on chest area. This altered the ability of chest cavity to 
expand, hence disrupting accuracy of spirometry test. The 
decrease in FVC value due to lung fibrosis is the one that was 
supposed to be measured. In addition to that, the mean age of 
subjects in this study was 42 years old, in which their volume of 
lungs might had already decreased. Secondly, KL-6 serum in this 
study was measured using ELISA method instead of 
chemiluminescent enzyme immunoassay (CLEIA) method which 
was used in most of KL-6 studies in the other countries. However, 
in Indonesia, CLEIA method was not possible to be performed on 
daily clinical practice. 
 
KL-6 serum with mRSS 
This study also showed no significant correlation between 
KL-6 serum and mRSS. This was consistent with cohort study 
from Cao et al in China who reported lack of correlation 
between KL-6 serum and mRSS score in 141 SSc patients (60 
dSSc patients and 81 lSSc).21 This lack of correlation was also 
reported in Hant et al study, named Scleroderma Lung Study 
(SLS), in North America.22 Benyamin et al also reported that 
there was no significant level of KL-6 serum in dSSc patients 
compared to lSSc.20  
On the other hand, Bonella et al reported different results. 
They reported that there was a significant correlation between 
KL-6 and mRSS score (r= 0.71, p<0.0001).19 However, they 
include 10 lSSc and only 15 dSSc patients, a fewer amount of 
subjects compared to the other studies.  
We could not differentiate whether the restrictive lung 
disorder was caused by lung fibrosis or caused by skin fibrosis on 
chest area, which might affect the results of this study. The 
measurement of KL-6 serum in this study used KL-6 / Human 
 
30 Indonesian Journal of Rheumatology 2019; Vol 11 No. 2
MUC-1, in which has not been used in any 
published study and might need some calibrations. 
 
Conclusion 
There was no correlation between serum KL-6 
levels with FVC and mRSS value of patient with 
restritive lung disease in diffuse type systemic 
sclerosis. Further study analyzing KL-6 serum with 
lung fibrosis in SSc patients, diffuse and limited 
type, using HRCT is warranted. 
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